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KEYWORDS	
	 A	micellar	liquid	chromatographic	method	was	developed	for	determination	of	Itraconazole	inbulk,	 dosage	 form	and	human	plasma	using	 µBondapack	 cyano	 column	 and	 a	mobile	 phase
consisting	of	0.1	M	sodium	dodecyl	sulphate,	20%	1‐propanol,	0.3%	triethylamine	in	0.02	M
orthophosphoric	 acid	 (pH	 =	 3.5).	 The	 UV	 detection	 was	 achieved	 at	 258	 nm.	 Various
chromatographic	 parameters	 were	 studied,	 e.g.	 types	 of	 columns,	 pH	 of	 mobile	 phase,
concentration	 of	 sodium	 dodecyl	 sulphate,	 1‐propanol,	 triethylamine,	 etc	 .The	method	 was
linear	over	 the	concentration	range	16.4‐320.0	µg/mL	with	regression	coefficient	0.999	and
limit	of	detection	5.4	µg/mL	in	bulk.	Inter	and	intra‐day	results	showed	%RSD	<	1.49%.	The
result	obtained	by	 the	proposed	method	was	compared	with	 that	obtained	by	the	reference
HPLC	 technique.	 Furthermore,	 the	 proposed	 method	 was	 successfully	 applied	 as	 stability‐
indicating	method	for	determination	of	Itraconazole	under	different	stressed	conditions.	The
method	 showed	 good	 selectivity,	 repeatability,	 linearity	 and	 sensitivity	 according	 to	 the
evaluation	of	the	validation	parameters.	
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1.	Introduction	
	
Itraconazole	 (ITC),	 is	 a	 triazole	 compound,	 chemically	
described	 as	 (2R,4S)‐rel‐1‐(butan‐2‐yl)‐4‐{4‐[4‐(4‐{[(2R,4S)‐2‐
(2,4‐dichlorophenyl)‐2‐(1H‐1,2,4‐triazol‐1‐ylmethyl)‐1,3‐dioxo	
lan‐4‐yl]methoxy}phenyl)piperazin‐1‐yl]phenyl}‐4,5‐dihydro‐
1H‐1,2,4‐triazol‐5‐one	 (Figure	 1).	 It	 is	 an	 orally	 active	 anti‐
fungal	 drug	 and	 extensively	 metabolized	 in	 the	 liver	 by	 the	
cytochrome	 P450	 isoenzymes.	 ITC	 inhibits	 fungi	 ergosterol	
synthesis.	Depletion	of	ergosterol	in	fungal	membrane	disrupts	
the	structure	and	many	functions	of	 fungal	membrane	 leading	
to	inhibition	of	fungal	growth	[1].	
	
		
Figure	1.	Chemical	structure	of	ITC.	
	
ITC	bulk	drug	is	official	in	British	pharmacopeia	[2]	and	in	
European	 pharmacopeia	 [3]	 and	 assayed	 using	 non‐aqueous	
titration.	
Many	 methods	 for	 analysis	 of	 the	 cited	 compound	 have	
been	 reported,	 e.g.	 high	 pressure	 liquid	 chromatography	
(HPLC)	[4‐12],	liquid	chromatography‐mass	spectrometry	(LC‐
MS‐MS)	 [13‐16],	 electrokinetic	 chromatography	 [17],	micellar	
electrokinetic	 chromatography	 [18],	 capillary	 electrophoresis	
[19,20]	 and	 spectrophotometric	 methods	 [21,22].	 In	 reverse	
phase	 high‐performance	 liquid	 chromatography	 (RP‐HPLC),	
each	 component	 interacts	 with	 the	 stationary	 phase	 in	 a	
different	 manner	 depending	 upon	 its	 polarity	 and	 hydro‐
phobicity.	Thus,	a	separation	of	components	is	achieved	based	
on	 polarity.	 The	 addition	 of	 micelles	 to	 the	 mobile	 phase	
introduces	a	third	phase	into	which	the	solutes	may	partition.	
Micellar	liquid	chromatography	(MLC)	is	a	form	of	reversed	
phase	 liquid	 chromatography	 that	 uses	 an	 aqueous	 micellar	
solutions	 as	 the	 mobile	 phase.	 The	 use	 of	 micelles	 in	 high	
performance	 liquid	 chromatography	 was	 first	 introduced	 by	
Armstrong	 and	 Henry	 in	 1980	 [23].	 The	 technique	 is	 used	
mainly	 to	 enhance	 retention	and	 selectivity	of	 various	 solutes	
that	 would	 otherwise	 be	 inseparable	 or	 poorly	 resolved.	
Micelles	 are	 composed	 of	 surfactant,	 or	 detergent,	monomers	
with	 a	 hydrophobic	 moiety,	 or	 tail,	 on	 one	 end,	 and	 a	
hydrophilic	moiety,	or	head	group,	on	the	other.	The	polar	head	
group	may	be	anionic,	 cationic,	 zwitterionic,	or	non‐ionic.	The	
most	 commonly	used	surfactant	 in	MLC	 is	 the	anionic	 sodium	
dodecyl	sulphate	(SDS).	When	the	concentration	of	a	surfactant	
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in	 solution	 reaches	 its	 critical	micelle	 concentration	 (CMC),	 it	
forms	 micelles	 which	 are	 aggregates	 of	 the	 monomers.	 The	
CMC	 is	 different	 for	 each	 surfactant,	 as	 is	 the	 number	 of	
monomers	which	make	up	the	micelle,	termed	the	aggregation	
number	 (AN).	 In	 MLC,	 there	 are	 three	 partition	 coefficients	
which	 must	 be	 taken	 into	 account.	 The	 solute	 will	 partition	
between	the	water	and	the	stationary	phase,	the	water	and	the	
micelles,	and	 the	micelles	and	 the	stationary	phase,	so	gives	a	
large	versatility	to	this	technique	and	make	it	appropriate	for	a	
wide	range	of	solutes	that	can	be	separated	in	one	run.	
Many	of	the	characteristics	of	micelles	differ	from	those	of	
bulk	solvents.	For	example,	the	micelles	are,	by	nature,	spatially	
heterogeneous	with	a	hydrocarbon,	nearly	anhydrous	core	and	
a	highly	solvated,	polar	head	group.	They	have	a	high	surface‐
to‐volume	ratio	due	to	their	small	size	and	generally	spherical	
shape.	 Their	 surrounding	 environment	 (pH,	 ionic	 strength,	
buffer	 ion,	 presence	 of	 a	 co‐solvent,	 and	 temperature)	 has	 an	
influence	 on	 their	 size,	 shape,	 critical	 micelle	 concentration,	
aggregation	number	and	other	properties.		
The	main	 limitation	 in	 the	 use	 of	MLC	 is	 the	 reduction	 in	
efficiency	 (peak	 broadening)	 that	 is	 observed	 when	 purely	
aqueous	 micellar	 mobile	 phases	 are	 used	 [24].	 Several	
explanations	for	 the	poor	efficiency	have	been	theorized.	Poor	
wetting	of	the	stationary	phase	by	the	micellar	aqueous	mobile	
phase,	 slow	 mass	 transfer	 between	 the	 micelles	 and	 the	
stationary	phase,	and	poor	mass	transfer	within	the	stationary	
phase	have	all	been	postulated	as	possible	causes.	To	enhance	
efficiency,	 the	 most	 common	 approaches	 have	 been	 the	
addition	 of	 small	 amounts	 of	 organic	 modifiers,	 particularly	
alcohol,	and	increasing	the	column	temperature.	Care	needs	to	
be	taken	when	determining	how	much	organic	to	add.	Too	high	
a	 concentration	 of	 the	 organic	 may	 cause	 the	 micelle	 to	
disperse,	 but	 a	 generally	 accepted	 practice	 is	 to	 keep	 the	
volume	percentage	of	organic	below	15‐20%.	
Despite	the	reduced	efficiency	verses	RP‐HPLC,	hundreds	of	
applications	 have	 been	 reported	 using	 MLC.	 One	 of	 the	 most	
advantageous	 is	 the	 ability	 to	 directly	 inject	 physiological	
fluids.	 Micelles	 have	 an	 ability	 to	 solubilize	 proteins	 which	
enables	 MLC	 to	 be	 useful	 in	 analyzing	 untreated	 biological	
fluids	such	as	plasma,	serum,	and	urine.	MLC	is	a	better	choice	
than	 ion‐exchange	 LC	 or	 ion‐pairing	 LC	 for	 separation	 of	
charged	 molecules	 and	 mixtures	 of	 charged	 and	 neutral	
species.	 Analysis	 of	 pharmaceuticals	 by	 MLC	 is	 also	 gaining	
popularity.	 Another	 novel	 application	 of	 MLC	 involves	 the	
separation	and	analysis	of	inorganic	compounds,	mostly	simple	
ions.	This	is	a	relatively	new	area	for	MLC.	
The	aim	of	this	work	is	to	perform	more	accurate,	reliable,	
fast	 and	 validated	 MLC	 method	 for	 determination	 of	 ITC	 in	
bulk,	dosage	form	and	spiked	human	plasma	with	a	simple	and	
rapid	 sample	 preparation	 especially	 for	 the	 routine	 analysis.	
Different	 chromatographic	 parameters	 were	 investigated	 to	
select	 the	 optimum	 conditions	 for	 the	 separation	 and	 for	
applying	 as	 stability‐indicating	method	 for	 determination	 ITC	
under	 different	 stress	 conditions.	 The	 result	 obtained	 by	 the	
proposed	 method	 was	 compared	 with	 that	 obtained	 by	 the	
HPLC	technique	[2].	The	method	was	validated	according	to	the	
international	 conference	 on	 harmonization	 guidelines	 (ICH)	
[25].	
	
2.	Experimental	
	
2.1.	Materials	
	
ITC	 (99.9%	 purity)	 was	 kindly	 supplied	 by	 Multiapex	
Pharma	Drug	 Company	 (Egypt).	 The	pharmaceutical	 products	
used	were	 (1)	 Itrapex	 capsules	 (Apex	pharma	Co.,	 Egypt),	 (2)	
Itracon	capsules	 (Global	Napi	pharmaceuticals	Co.,	Egypt),	 (3)	
Itranox	 capsules	 (Adwia	Pharmaceutical	 Co.,	 Egypt).	All	 drugs	
contain	 100	 mg	 ITC/capsule.	 They	 were	 obtained	 from	 local	
pharmacies.	
Plasma	samples	were	obtained	from	Egyptian	Research	and	
Development	Company	and	kept	frozen	until	using	after	gentle	
thawing.	
	
2.2.	Reagents	and	chemicals	
	
All	Reagents	were	of	Analytical	Reagent	Grade	and	solvents	
were	 of	HPLC	 grade.	High	purity	water	was	 obtained	 by	 Elga	
Labwater,	Prima	7	(UK)	and	it	was	used	throughout	the	study.	
Methanol,	 1‐propanol	 and	 acetonitrile	 (HPLC	 grade)	were	
obtained	 from	 Sigma‐Aldrich	 (Germany).	 Ortho‐phosphoric	
acid	 (85%,	 w:v),	 triethylamine	 (TEA)	 and	 sodium	 dodecyl	
sulphate	 (SDS,	 99%)	 were	 obtained	 from	 Riedel‐deHäen	
(Sleeze,	Germany).	Sodium	Hydroxide,	Hydrochloric	acid	(32%,	
w:v)	were	purchased	from	El‐Nasr	Company,	Egypt.	Hydrogen	
peroxide	(30%,	w:v)	was	obtained	 from	Luna	industrial	group	
(6th	of	October	City,	Egypt).	
	
2.3.	Instrumentations	
	
The	MLC	method	was	performed	on	a	Gilson	HPLC	system	
equipped	 with	 a	 UV‐VIS	 156	 detector	 and	 Gilson	 321	 pump.	
(Middleton,	 USA).	 Analytical	 data	 is	 stored	 in	 a	 computer	
equipped	 with	 Unipoint	 software	 and	 connected	 to	 the	
chromatographic	 system	 by	 a	 Gilson	 system	 interface.	 Vortex	
used	 was	 VWR	 VV3	 S540	 International	 West	 Charter‐USA.	
Centrifuge	used	was	centurion,	(West	Sussex‐UK).	The	pH	was	
measured	with	Jenway	pH	meter,	3510,	(Essex‐UK).	The	mobile	
phase	 was	 filtered	 through	 Charles	 Austen	 Pumps	 Ltd.	 filter,	
model‐B100	 SE	 (England,	UK)	 using	 0.45	μm	milli‐pore	 filters	
(Gelman,	 Germany).	 UV‐visible	 spectrophotometer	 used	 was	
Jasco,	 V‐530,	 (Tokyo,	 Japan).	 Ultrasonic	 bath	 used	 was	 Falc,	
(Treviglio‐Italy).	
	
2.4.	Chromatographic	conditions	
	
MLC	was	performed	on	a	µBondapack	Cyano	column	(3.9	×	
150	mm,	5	µm	particle	size),	waters	Corporation,	Ireland	using	
micellar	 mobile	 phase	 consisting	 of	 0.1	 M	 sodium	 dodecyl	
sulphate	 (SDS),	20%	1‐propanol,	 0.3%	 triethylamine	 (TEA)	 in	
0.02	M	ortho‐phosphoric	acid	(pH	=	3.5).	The	mobile	phase	was	
filtered	and	sonicated	for	30	min	before	use.	The	flow	rate	was	
2.0	mL/min	and	sample	injection	volumes	were	20	µL	at	room	
temperature	(25	°C).	The	UV	detector	was	operated	at	258	nm.	
	
2.5.	Standard	solutions	
	
Standard	stock	solution	(400	µg/mL)	of	 ITC	was	prepared	
by	dissolving	10	mg	 ITC	 in	25	mL	methanol	 then	 the	solution	
was	sonicated	in	an	ultrasonic	bath	for	5	minutes.	The	solutions	
were	 found	 to	 be	 stable	 for	 3	 days	 at	 room	 temperature.	
Working	 standard	 solutions	 (120‐320	 µg/mL)	were	 prepared	
by	appropriate	dilutions	of	the	standard	stock	solution	with	the	
mobile	phase.	
	
2.6.	Preparation	of	pharmaceutical	products	
	
Take	 the	 contents	 of	 20	 capsules	 and	 determine	 the	
average	weight	of	 content	per	 capsule.	Accurate	weight	of	 the	
powder	 equivalent	 to	 10	 mg	 ITC	 was	 dissolved	 in	 25	 mL	
methanol	then	sonication	for	15	min	and	filtered.	
	
2.7.	Plasma	sample	extraction	
	
1	 mL	 of	 human	 plasma	was	 transferred	 into	 a	 centrifuge	
tube,	 spiked	 with	 1	 mL	 of	 ITC	 and	 deprotenized	 with	 2	 mL	
acetonitrile	(ACN),	then	vortex.	Final	concentrations	were	125,	
150	 and	 175	 µg	 ITC/mL,	 respectively.	 The	 solutions	 were	
centrifuged	 at	 5000	 rpm	 for	 15	 minutes.	 Then,	 the	 solutions	
were	 filtered	 through	 a	 disposable	 syringe	 filter	 (0.45	 µm)	
before	column	injection.	
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Table	1.	Optimization	of	chromatographic	conditions	for	the	separation	of	ITC.	
Parameter	 Variation	 No	of	theoretical	plates		
(N)	
Capacity	factor		
(K’)
Selectivity	factor		
(α)
Peak	width		
(10%)	
Tailing	factor	
(tf)	
pH	 2.5	 640	 2.15 6.26 0.59	 1.46
3.5	 505	 1.43	 4.77	 0.38	 1.23	
4.5	 465	 1.39 4.73 0.36	 1.25
Conc.	of	SDS	(M)	 0.07	 382	 2.52 5.66 0.76	 1.23
0.1	 522	 1.60	 4.92	 0.35	 1.30	
Conc.	of	1‐propanol	(%	v:v)	 10	 103	 1.86 2.89 0.88	 1.20
14	 177	 1.76	 2.80	 0.74	 1.26	
20	 522	 1.60 4.83 0.37	 1.30
Flow	rate	(mL/min)	 1.0	 525	 4.54 7.08 1.25	 1.42
1.5	 562	 4.58 7.34 0.98	 1.44
2.0	 575	 1.60 3.60 0.36	 1.23
Conc.	of	TEA	(%	v:v)	 0.2	 96	 1.69	 2.75	 0.70	 1.30	
0.3	 505	 1.60 3.60 0.36	 1.20
	
	
2.8.	Sample	degradation	
	
An	 appropriate	 amount	 of	 ITC	 at	 a	 final	 concentration	 of	
500	µg/mL	in	1	N	alcoholic	HCl	was	left	for	24	hours	then	the	
solution	 was	 filtered	 and	 4	 mL	 was	 taken	 into	 10	 mL	
volumetric	 flask	 and	 the	 volume	 was	 completed	 with	 the	
mobile	 phase,	 sonicated	 and	 triplicate	 20	 µL	 injections	 were	
made.	The	same	experiment	was	repeated	but	in	1	N	alcoholic	
NaOH,	 30%	 H2O2	 or	 the	 solutions	 of	 ITC	 were	 left	 in	 the	
sunlight	 for	 24	 hrs.	 Each	 experiment	 was	 carried	 out	 in	
triplicate	 and	 all	 solutions	 were	 injected	 in	 triplicate.	 The	
nominal	contents	of	ITC	were	calculated	using	the	constructed	
calibration	 graph	 or	 from	 the	 corresponding	 regression	
equation	
	
3.	Results	and	discussion	
	
The	proposed	MLC	method	represents	a	rapid	and	sensitive	
stability‐indicating	 assay	 method	 for	 the	 simultaneous	
determination	 of	 ITC	 in	 bulk	 and	 commercial	 capsules.	 By	
virtue	 of	 its	 high	 sensitivity,	 it	 was	 applied	 for	 the	
determination	of	ITC	in	human	plasma	with	no	need	for	tedious	
sample	 pre‐treatment	 steps.	 Moreover,	 it	 was	 extended	 to	
investigate	the	inherent	stability	of	ITC	under	different	stressed	
conditions.		
Different	 parameters	 affecting	 the	 chromatographic	
performance	of	 ITC	were	carefully	studied	 in	order	 to	achieve	
the	most	 suitable	 chromatographic	 system.	 The	 results	 of	 the	
optimization	study	can	be	summarized	as	follows:	
	
3.1.	Choice	of	appropriate	detection	wavelength	
	
ITC	exhibits	maximum	absorption	at	258	and	262	nm	when	
measured	 in	 the	 mobile	 phase	 and	 in	methanol,	 respectively.	
So,	258	nm	was	selected	as	it	gives	reasonable	sensitivity.	The	
absorption	 spectrum	 of	 ITC	 in	 the	 micellar	 mobile	 phase	 is	
shown	in	Figure	2.	
	
		
Figure	2.	Absorption	spectrum	of	ITC	in	the	micellar	mobile	phase.
	
3.2.	Choice	of	column	
	
To	investigate	the	chromatographic	performance,	different	
columns	 had	 been	 tried,	 these	 include	 reversed‐phase	 C8,	
reversed‐phase	 C18,	 bonded	 phase	 cyano	 and	 bonded	 phase	
phenyl	 columns.	 Experimental	 trials	 revealed	 that	 the	
µBondapack	Cyano	column	(3.9	×	150	mm,	5	µm	particle	size)	
was	 the	 most	 suitable	 one	 giving	 narrower	 symmetric	 peaks	
and	 highest	 number	 of	 theoretical	 plates	within	 a	 reasonable	
analysis	time	as	shown	in	Figure	3	and	Table	1.	
	
		
Figure	 3.	 ITC	 Chromatogram	 under	 optimum	 chromatographic	 conditions	
using	 µbondapack	 cyano	 column	 (a)	 Solvent	 front	 peak	 (b)	 ITC	 peak	 (200	
µg/mL).	
	
	
3.3.	Mobile	phase	composition	
	
To	 achieve	 the	 appropriate	 chromatographic	 conditions,	 the	
mobile	phase	composition	was	optimized	to	provide	sufficient	
selectivity	 and	 sensitivity	 in	 a	 short	 separation	 time.	 The	
studied	 variables	 included;	 the	 pH	 of	 the	 mobile	 phase,	 flow	
rate,	 concentration	 of	 SDS,	 organic	 modifier	 and	 TEA.	 The	
results	of	such	optimization	study	are	presented	in	Table	1.	
	
3.3.1.	pH	of	the	mobile	phase		
	
The	effect	of	pH	of	 the	mobile	phase	was	studied	over	 the	
range	 of	 2.5‐4.5.	 Increasing	 the	 pH	 of	 the	mobile	 phase	more	
than	3.5	caused	increase	in	the	retention	time	of	ITC.	Therefore,	
pH	=	3.5	was	selected	as	the	optimum	pH	value	for	the	mobile	
phase	yielding	highest	number	of	 theoretical	plates	with	good	
peak	shape	and	lowest	peak	tailing.	
	
3.3.2.	Concentration	of	SDS	
	
SDS	 concentration	was	varied	over	 the	 range	of	 0.07‐0.10	
M.	Mobile	phase	containing	0.07	M	SDS	resulted	in	very	broad	
peak.	 The	 retention	 time	 of	 the	 drug	 decreased	 as	 the	molar	
concentration	of	SDS	increased.		
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Table	2.	Accuracy	of	the	proposed	MLC	method	for	the	determination	of	ITC.	
Parameter	 Proposed	method	 Comparison	method	[2]	
Conc.	taken	(µg/mL)	 Conc.	found	(µg/mL) %	Found	* %	Found	*	
120	 121.6 101.3 100.9	
160	 157.2	 98.3	 99.1	
200	 200.9 100.5 102.0	
240	 240.3	 100.1	 100.2	
320	 319.9 100.0 99.2
x±SD	 	 	 100.04±1.1 100.3±1.2	
t	 0.3	(1.9)	**	
F	 1.2	(6.4)**	
*	Each	result	is	the	average	of	three	separate	determinations.		
**	Values	between	parentheses	are	the	tabulated	t	and	F	values	at	n	=	15	and	p	=	0.05	[26].	
	
	
The	best	 compromise	 in	 terms	of	 run	 time,	 efficiency	 and	
peak	 symmetry	 was	 achieved	 upon	 using	 a	 mobile	 phase	
containing	0.10	M	SDS.	
	
3.3.3.	Concentration	of	organic	modifier	
	
Concentration	of	1‐propanol	was	varied	over	 the	 range	of	
10‐20%.	 As	 expected,	 the	 retention	 of	 ITC	 decreases	 as	
percentage	 of	 organic	 modifier	 increases.	 In	 addition,	 peak	
broadening	was	observed	at	low	concentrations	of	1‐propanol.	
A	 concentration	 of	 20%	 of	 1‐propanol	 was	 chosen	 as	 the	
optimal	 concentration,	 where	 it	 offers	 a	 good	 combination	 of	
peak	 symmetry	 and	 analysis	 time.	 Zero	 concentration	 of	
propanol	was	tried	and	no	peak	appears	till	20	min.		
	
3.3.4.	Concentration	of	triethyl	amine	(TEA)	
	
TEA	is	added	to	the	mobile	phase	to	bind	the	silanol	groups.	
This	reduces	the	tailing	of	basic	compounds	which	is	not	due	to	
the	micellar	phase.	To	study	the	influence	of	the	concentration	
of	TEA	on	the	peak	of	ITC,	it	was	varied	over	the	range	of	0.2‐
0.3%.	 It	was	 found	 that	 the	peak	 tailing,	peak	asymmetry	and	
number	 of	 theoretical	 plates	 are	 better	 with	 0.3%	 TEA.	 The	
recorded	performance	parameters	were	listed	in	Table	1.	
	
3.3.5.	Flow	rate	of	the	mobile	phase	
	
The	effect	of	flow	rate	of	the	mobile	phase	on	the	retention	
of	ITC	was	investigated	over	the	range	of	1.0‐2.0	mL/min.	Flow	
rate	 of	 2.0	mL/min	was	 chosen	 since	 it	 provides	 better	 peak	
shape	within	a	reasonable	time.	
After	optimization	of	 these	variables,	best	peak	shape	and	
lowest	peak	tailing	were	achieved	with	well‐defined	peaks	and	
good	sensitivity	within	a	reasonable	analytical	run	time.	Figure	
3	represents	a	chromatogram	 indicating	the	good	retention	of	
ITC	under	the	optimum	chromatographic	conditions.	
	
3.4.	Method	validation	
	
The	 validity	 of	 the	 proposed	 method	 was	 assessed	 by	
studying	 the	 following	 parameters	 in	 accordance	 to	 ICH	
guideline	 [25]:	 linearity,	 LOD,	 LOQ,	 accuracy,	 precision,	
selectivity,	 sample	 solution	 stability,	 mobile	 phase	 stability,	
system	suitability	and	robustness.	
	
3.4.1.	Linearity		
	
Under	 the	 optimum	 chromatographic	 conditions,	 a	 linear	
relationship	was	 established	over	 the	 concentration	 ranges	 of	
16.4‐320.0	 µg/mL	 ITC	 (Figure	 4)	 with	 good	 correlation	
coefficient	(r)	and	relative	standard	deviation	(R.S.D.)	(1.05%)	
according	to	the	following	regression	equation:	
	
y	=	15545	x	–	40170	(r	=	0.9997)	 	 	 (1)	
	
Limit	of	detection	(LOD)	(The	lowest	concentration	that	can	
be	determined)	and	Limit	of	quantification	(LOQ)	(The	 lowest	
concentration	 of	 a	 substance	 that	 can	 be	 quantified	 with	
acceptable	 precision	 and	 accuracy)	 for	 ITC	 were	 calculated	
according	to	ICH	Q2	(R1)	recommendation	[25].	LOD	and	LOQ	
were	found	5.4	and	16.4	µg/mL,	respectively.	
	
		
Figure	4. Calibration	curve	for	MLC	determination	of	ITC.
	
3.4.2.	Accuracy		
	
To	prove	the	accuracy	of	the	proposed	method,	the	results	
of	the	assay	of	ITC	in	pure	form	by	the	proposed	MLC	method	
were	 compared	 with	 those	 obtained	 using	 a	 reference	 HPLC	
method	 [2].	 Statistical	 comparison	 using	 t‐test	 and	 F‐test	
revealed	no	significant	differences	between	the	performance	of	
the	 two	 methods	 regarding	 the	 accuracy	 and	 precision,	
respectively	as	illustrated	in	Table	2.		
	
3.4.3.	Precision	
	
Intra‐day	precision	was	achieved	by	six	replicate	determination	
of	 200	 µg/mL	 in	 the	 three	 dosage	 forms	 on	 three	 successive	
times	 in	 the	 same	 day.	 Inter‐day	 precision	was	 performed	 as	
intra‐day	precision	but	on	 three	successive	days.	 Small	values	
of	%error	 and	%RSD	 revealed	 the	 precision	 of	 the	 proposed	
method.	The	results	are	illustrated	in	Table	3.	
	
3.4.4.	Selectivity	
	
The	 Selectivity	 of	 the	 proposed	 MLC	 method	 was	
established	 by	 its	 ability	 to	 determine	 ITC	 in	 commercial	
capsules	 without	 interference	 from	 common	 tablet	 additives.	
The	 common	 capsule	 additives	 did	 not	 show	 any	 interfering	
peaks	 at	 the	 retention	 times	 of	 the	 drug,	 which	 proved	 the	
homogeneity	and	purity	of	 the	peak.	Furthermore,	 to	evaluate	
the	 specificity	 of	 the	 method	 to	 determine	 ITC	 in	 human	
plasma,	 blank	 plasma	 was	 diluted	 with	 the	 micellar	 mobile	
phase	 and	 injected	 under	 the	 recommended	 chromatographic	
conditions.	 No	 endogenous	 interference	 was	 observed	 at	 the	
retention	time	of	ITC,	proving	the	specificity	of	the	method.		
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Table	3.	Precision	data	of	the	proposed	method	for	the	determination	of	ITC	in	dosage	forms.	
Parameters	 %	Found±SD	 %RSD	 %Error	
Intra‐day	precision	
Itrapex	cap	 102.8±1.4	 1.36 0.3	
Itracon	cap	 99.2±1.2	 1.21 0.3	
Itranox	cap		 103.5±0.5	 0.51 0.1	
Inter‐day	precision	
Itrapex	cap	 103.4±1.2	 1.16 0.3	
Itracon	cap		 98.2±1.2	 1.22 0.3	
Itranox	cap	 102.2±0.8	 0.78 0.2	
	
Table	4.	SST	parameters	for	the	developed	200	µg/mL	MLC	method.	
Parameters	 ITC	
No	of	theoretical	plates,	N	 505	
Capacity	factor,	K’	 2.02	
Selectivity	factor,	α	 2.02	
Resolution	factor,	Rs	 4.68	
	
	
Forced	 degradation	 studies	 were	 also	 performed	 to	
evaluate	 the	 validity	 of	 the	 method.	 The	 results	 obtained	
indicated	 that	 the	proposed	MLC	method	 is	selective	and	able	
to	determine	ITC	in	presence	of	its	degradation	products.	
	
3.4.5.	Sample	solution	stability	and	mobile	phase	stability	
	
Evaluation	of	 the	stability	of	 ITC	solution	was	achieved	by	
quantification	of	ITC	on	three	successive	days	and	comparison	
to	 freshly	 prepared	 solution.	 Similarly,	 the	 stability	 of	 the	
mobile	 phase	 was	 checked.	 No	 significant	 changes	 were	
observed	 in	 standard	 solution	 or	 mobile	 phase	 responses,	
proved	that	they	were	stable	up	to	3	days.	
	
3.4.6.	System	suitability	test	(SST)	
	
	Evaluation	 of	 SST	 parameters	 was	 performed	 during	 the	
development	 and	 optimization	 of	 the	 method.	 Moreover,	 to	
ascertain	the	effectiveness	of	the	final	operating	system,	it	was	
subjected	 to	 suitability	 testing.	 The	 test	 was	 performed	 by	
injecting	 the	 standard	 sample	 in	 triplicate	 and	 the	 SST	
parameters	 were	 calculated	 as	 reported	 by	 USP	 [27]	 which	
include	 capacity	 factor	 (k’),	 selectivity	 factor	 (α),	 Resolution	
factor	(Rs),	column	efficiency	(number	of	theoretical	plates,	N).	
The	final	SST	parameters	under	the	optimum	chromatographic	
conditions	are	summarized	in	Table	4.	
	
3.4.7.	Robustness	
	
To	assess	the	robustness	of	the	proposed	MLC	method,	the	
chromatographic	 conditions	were	deliberately	 altered	 such	as	
concentration	of	1‐propanol	(20±0.5%,	v:v),	strength	of	ortho‐
phosphoric	 acid	 (0.02±0.005	 M),	 concentration	 of	 TEA	
(0.3±0.01%).	 The	 efficiency	 of	 the	 separation	 of	 ITC	 was	 not	
affected	 indicating	 the	 reliability	 of	 the	 proposed	 method.	
Therefore,	 the	 method	 is	 robust	 to	 the	 small	 changes	 in	
experimental	conditions.	
	
3.5.	Applications	
	
3.5.1.	Application	of	the	proposed	method	to	the	
determination	of	ITC	in	capsules	
	
The	 developed	 MLC	 method	 was	 applied	 successfully	 for	
the	assay	of	 ITC	in	commercial	capsules	as	shown	in	Figure	5.	
The	 results	 obtained	 by	 the	 developed	 MLC	 method	 were	
statistically	 compared	 with	 those	 of	 the	 reference	 HPLC	
method	 [2]	 using	 the	 t‐test	 and	 F‐test.	 The	 results	 show	 that	
there	 were	 no	 significant	 differences	 between	 the	 developed	
and	 reference	 methods	 regarding	 accuracy	 and	 precision,	
respectively	as	illustrated	in	Table	5.	
The	 proposed	 method	 showed	 satisfactory	 results	 for	
determination	 of	 ITC	 in	 spiked	 human	 plasma.	 The	 assay	
results	using	the	proposed	method	are	summarized	in	Table	6.		
3.5.2.	Application	of	the	proposed	method	to	the	
determination	of	ITC	in	spiked	human	plasma	
	
MLC	allows	biological	samples	to	be	analyzed	without	prior	
tedious	 pre‐treatment	 for	 plasma	 protein	 precipitation	 or	
elimination	 of	 other	 interfering	 substances,	 thus	 considerably	
reducing	the	cost	and	analysis	time.	The	proposed	MLC	method	
was	successfully	applied	to	the	determination	of	ITC	in	spiked	
human	plasma.	
	
		
		
		
Figure	5.	Representative	chromatogram	showing	200	µg/mL	ITC	in	different	
capsule	formulations,	where:	(A)	Itracon	capsule	(B)	Itrapex	capsule	(C)	
Itranox	capsule.	
	
Table	 5.	 Application	 of	 the	 proposed	 and	 reference	 method	 for	 the	
determination	of	ITC	in	capsules.	
Pharmaceutical	
preparation	
%	Found *,	mean±	SD	
Proposed	 Reference	[2]	
Itrapex	cap 99.3±1.2 99.6±1.5	
t	** 0.3 ‐	
F	** 1.7 ‐	
Itranox	cap	 105.1±0.5	 104.4±0.8	
t	** 0.3 ‐	
F	** 2.3 ‐	
Itracon	cap 106.4±0.6 106.6±0.6	
t	** 0.4 ‐	
F	** 1.2 ‐	
*	 Each	 result	 is	 the	 average	 of	 five	 separate	 determinations	 and	 each	 one	
repeated	three	times.		
**	The	tabulated	t	=	1.9	and	F	=	6.4	at	n	=	15	and	p	=	0.05	[26].	
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Table	6.	Assay	Results	for	the	determination	of	ITC	in	spiked	human	plasma	
using	the	proposed	method.	
Parameter	 Conc.	added	
(µg/mL)	
Conc.	found	
(µg/mL)	
%	Recovery	*
Spiked	plasma	 125	 125.4	 100.3	
150	 145.6	 97.1
175	 166.2	 94.9
Mean	%±SD	 97.5±2.7	
%	R.S.D	 2.8	
%	Error	 0.9	
*	Each	result	is	the	average	of	three	separate	determinations.	
	
3.5.3.	Results	of	stress	testing	studies	
	
Stability	testing	of	ITC	was	performed	under	various	stress	
conditions	 in	 order	 to	 assure	 the	 selectivity	 and	 provide	 an	
indication	of	the	stability‐indicating	properties	of	the	proposed	
MLC	method.	
The	 studied	 compound	 is	 found	 to	 be	 highly	 labile	 to	
alkaline	 hydrolysis	 which	 resulted	 in	 about	 85	 and	 82%	
degradation	of	ITC	in	itrapex	and	itracon	capsule,	respectively,	
while	the	peak	of	ITC	in	itranox	capsule	was	nearly	diminished	
as	illustrated	in	Figure	6.	Where	the	acidic	degradation	using	1	
N	 HCl	 for	 24	 hrs	 showed	 that	 about	 10%	 degradation	 in	 the	
three	dosage	 forms	as	 illustrated	 in	Figure	7.	Exposure	of	 ITC	
capsules	 to	 oxidative	 degradation	 by	 30%	 H2O2	 for	 24	 hrs,	
about	 69,	 63	 and	 65	 %	 degradation	 of	 ITC	 in	 itrapex	 cap.,	
itranox	 cap.	 and	 iracon	 cap.,	 respectively,	 as	 illustrated	 in	
Figure	8.	ITC	did	not	exhibit	any	degradation	peaks	that	could	
interfere	with	the	proposed	MLC	method.	No	degradation	was	
seen	under	photolytic	conditions.	
	
		
		
		
Figure	6.	Alkaline	degradation	of	200	µg/mL	ITC	in	its	three	dosage	forms.	
	
4.	Conclusion	
	
The	 proposed	 MLC	 method	 represents	 a	 new	 rapid	 and	
sensitive	stability‐indicating	assay	for	the	determination	of	ITC	
in	 bulk	 and	 commercial	 capsules.	 The	 proposed	 method	 was	
applied	 successfully	 for	 the	 determination	 of	 ITC	 in	 human	
plasma	with	no	need	for	tedious	sample	pre‐treatment	steps.	In	
addition,	the	proposed	method	was	extended	to	investigate	the	
inherent	stability	of	ITC	under	different	stress	conditions.	
		
	
		
	
		
Figure	7.	Acidic	degradation	of	200	µg/mL	ITC	in	its	three	dosage	forms.
	
	
		
	
		
	
		
Figure	8.	Oxidative	degradation	of	200	µg/mL	ITC	in	its	three	dosage	forms.	
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